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Unraveling the Genetics of Lymphocytic Thyroiditis using the Dog 
as a Model  
Abstract 
The domestic dog, with its unique genetic structure formed by domestication and 
recent breed creation, has been proven to be an excellent model for mapping 
disease genes. In this thesis, we use the dog as a model to investigate the prevalence 
and genetic background of canine lymphocytic thyroiditis (CLT), one of the most 
common immune related diseases in dogs. The canine phenotype has been carefully 
characterized and suggests a strong comparative value to human Hashimoto’s disease 
because of similar etiology, clinical signs and disease progression. Therefore, our aim 
was to gain increased knowledge about CLT and its relevance to human 
autoimmune thyroid disease, to benefit both dogs and humans.  
In our first study (paper I) we screened two birth cohorts (3-4 and 6-7 years old, 
respectively) for elevated serum levels of autoantibodies to thyroglobulin (TgAA) 
and thyroid stimulating hormone (TSH) and could estimate a very high prevalence 
of CLT in the giant schnauzer and the hovawart breeds. Next, we aimed at 
unraveling the genetic background of CLT in the same breeds, using two different 
approaches; a candidate gene approach followed by a genome-wide association 
analysis. Using the first approach we obtained evidence that DLA class II 
polymorphisms can function both as a genetic risk factor predisposing for the disease 
as well as a protective factor against the disease. Using genome wide association we 
identified two additional strong susceptibility loci located on chromosome 11 and 
X. Both regions harbour genes with known immune-regulatory functions and 
implicates three genes involved in NF-κB pathway. Given the reported role of  
NF-κB in many human autoimmune diseases, our results suggest CLT as an 
excellent genetic model for human thyroiditis.  
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Abbreviations 
ADAMTSL  ADAMTS-like protein 1 
AITD  autoimmune thyroid disease  
BB/W-rat   BioBreeding/Worcester rat  
BCOR  co-repressor of B-cell lymphoma 6 
BCL-6  B-cell lymphoma 6 
BNC2  basonuclin2 
bp   base pair 
CHV  canine hepatitis C virus 
CI confidence  interval 
CLT  canine lymphocytic thyroiditis 
CNTLN  centlein 
CS  cornell special strain  
CTLA-4  cytotoxic T lymphocyte antigen-4  
CYBB cytochrome-b  b-chain   
DLA  dog leukocyte antigen 
DMRTA1 DMRT-like  family  A1 
DMRTA2 DMRT-like  family  A2 
DNA deoxyribonucleic  acid 
EDTA ethylenediaminetetraacetic  acid 
ELAVL2  embryonic lethal, abnormal vision, Drosophila-like 2 
ELISA  enzyme-linked immunosorbent assay 
FCI  Fédération Cynologique Internationale  
FREM1  FRAS1 related extracellular matrix 1 
HCV  hepatitis C virus 
HLA  human leukocyte antigen 
IFN-a   interferon alpha 
IIT  interferon induced thyroiditis   9
IL-8   interleukin-8 
kb kilo  bases 
LANCL3  lanc-like protein 3 
LD  linkage disequilibrium  
LincRNA  long intergenic non-coding RNA 
Lyp  lymphoid-specific phosphatase  
MAF  minor allele frequency 
Mb mega  bases 
MHC  major histocompatibility complex 
MTAP  methylthioadenosine phosphorylase 
NF-kB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NFIB  nuclear factor I/B 
NOD non-obese  diabetic   
OMIA  Online Mendelian Inheritance in Animals 
OS obese  strain 
PBMC  peripheral blood mononuclear cells  
PCR polymerase  chain  reaction 
PLD   Polish lowland dog 
PTPN22  tyrosine phosphatase nonreceptor 22 
QQ-plot quantile-quantile  plot 
RNA ribonucleic  acid 
RPGR  retinitis pigmentosa GTPase regulator 
SAT spontaneous  autoimmune  thyroiditis 
SCID  severe combined immunodeficiency  
SKC  the Swedish Kennel Club  
SLE  systemic lupus erythematosus  
SNP  single nucleotide polymorphism 
T3 triiodinethyronine 
T4 thyroxine 
Tg thyroglobulin 
TgAA thyroglobulin  autoantibodies 
TILRR  toll-like/interleukin-1 receptor regulator  
TPO thyroperoxidase 
TSH  thyroid stimulating hormone 
TSHR  thyroid stimulating hormone receptor  
TSPAN7  tetraspanin 7 
WSS  Welsh springer spaniel 
XK  Membrane transport protein XK 
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Introduction  
The dog as an animal model for human disease 
The domestic dog (Canis familiaris) is truly man’s best friend. Not only has it 
been our loyal companion for at least 15 000 years (Savolainen et al., 2002; 
Vila et al., 1997; Wayne et al., 1997), but it can also help us to better 
understand the genetic background of many of our common diseases. 
Animal models have long been used to study basic biological functions or to 
identify genetic or environmental risk factors for disease development.   
Traditional model organisms such as the mouse and the rat have been, and 
still are, valuable tools for such research. However, high quality genome 
sequences for several domesticated species have recently been made 
available, adding important opportunities for comparative research in species 
closer to humans in terms of anatomy, physiology and genetics. The work 
in this thesis is based on genetic and epidemiologic studies of a common and 
naturally occurring disease in the dog, canine lymphocytic thyroiditis. 
 
The remarkable dog genome 
It is believed that the dog’s ancestor, the grey wolf (Canis lupus), coexisted 
with human in a mutually beneficial relationship, and that the first selection 
of wolves was based on the individuals non-aggression towards human 
(McGreevy & Nicholas, 1999). Eventually, man began to select and breed 
dogs possessing desirable behavioral- (hunting, guarding, retrieving) and 
morphological (size, scull shape, coat color and texture) characteristics, 
creating different types of dogs. But it was only recently, not more than 200 
years ago, that the actual breed creation and establishment of strict breed 
standards took place. Today, the domesticated dog population is divided 
into more than 350 breeds recognized by the international canine   12
organization Fédération Cynologique Internationale (FCI), each 
representing a closed population. The large number of breeds and breed 
variants implies breeding in genetically small populations. Also, common to 
many breeds is a founder event involving only a few individuals, the 
continuous use of popular sires and systematic inbreeding, further increasing 
genetic drift and loss of heterozygosity (Lindblad-Toh et al., 2005; 
McGreevy & Nicholas, 1999).  
The restrictive breeding strategies have created a reduced heterozygosity 
within breeds. However, the degree of genetic variation across breeds is 
extensive, much higher than the variation between human populations. Of 
the total existing genetic variation in dogs, 27% is observed between breeds, 
in humans the corresponding figure between populations is only 5-10% 
(Parker et al., 2004). 
Indeed humans have, from the genome of the grey wolf distilled most of 
all possible morphologic and behavioral variation, divided it and enriched it 
within more than 350 different genetic isolates and created the most diverse 
of all domesticated species, the domesticated dog. An event by some 
referred to as ‘one of the greatest genetic experiments ever’ (Ostrander & 
Wayne, 2005). 
 
Fewer markers, fewer individuals 
The unique population- and breed history of the dog have shaped its 
genome to offer great advantages for mapping traits. As a part of the Dog 
genome project linkage disequilibrium (LD) and haplotype blocks within 
and across breeds was defined (Lindblad-Toh et al., 2005). It was shown that 
within breeds haplotypes are large (0.5-1 Mb) and LD are 10-100 times 
more extensive than in human, reaching over several megabases. It was also 
found that large portions (up to 100 kb) of the haplotypes are shared across 
breeds, suggesting that genetic risk factors may be shared between breeds. In 
contrast, haplotypes across breeds are shorter and LD extends only tens of 
kilobases.  
The extensive haplotype structure of the dog allows mapping with far 
fewer markers compared to humans (Figure 1) (Lindblad-Toh et al., 2005). 
While human studies require 300 000 to a million markers, 10 000 to 
50 000 markers are sufficient to perform whole genome associations studies 
in the dog (Karlsson et al., 2007; Lindblad-Toh et al., 2005; Sutter & 
Ostrander, 2004). 
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Figure 1: The extensive linkage disequilibrium in the canine genome allows mapping with 
fewer markers than in humans. 
 
The low genetic variation within breeds also reflects the enrichment of a 
few strong genetic factors, allowing efficient mapping with fewer individuals 
than in human populations, which are much more diverse.  Lindblad-Toh 
and colleagues (2005) predicted that 20 cases and 20 controls should be 
sufficient for efficient mapping of recessive traits. For dominant traits 50 
cases and 50 controls should be sufficient, and for a complex trait, 100 cases 
and 100 controls should identify alleles conferring a 5 fold increased risk 
(Lindblad-Toh et al., 2005). Several successful studies identifying genetic risk 
factors for both monogenic and complex diseases later proved this 
prediction to be correct (Olsson et al., 2011; Wilbe et al., 2010; Karlsson et 
al., 2007; Salmon Hillbertz et al., 2007). 
 
Common disease, common genes, shared environment 
As a consequence of the reduced heterozygosity, domesticated dog breeds 
suffer from an excess of inherited diseases such as cancers, diabetes, epilepsy, 
cardiovascular and autoimmune diseases, all of which are also common in 
humans (OMIA, 2012; Karlsson & Lindblad-Toh, 2008; Lindblad-Toh et 
al., 2005; Ostrander et al., 2000). Clinical manifestation and disease 
progression is often similar between the two species. The database OMIA 
(Online Mendelian Inheritance in Animals) reports more than 500 genetic 
diseases in dogs, the majority indicated as potential models for human 
diseases (OMIA, 2012). Furthermore dogs, like humans, receive extensive 
medical care and reliable clinical diagnoses, which constitute another 
valuable benefit in genetic disease mapping. Most purebred dog populations 
also have extensive pedigree records in which to trace familiar genetic 
diseases.  
The genomes of dog and human are very similar. Comparative studies 
between the human, mouse and dog genome show that dog to human 
nucleotide sequence similarity is higher compared with the similarity   14
between dog and mouse. Dog have roughly the same number of genes 
(20 000, compared to 21 000 in humans), and the difference is mainly due 
to gene-family expansion. Also, a large proportion of genes identified in dog 
are orthologous to human genes (Lindblad-Toh et al., 2005), further 
strengthening the comparative value of the dog model.  
But humans and dogs do not only share a common history of several 
thousand years, disease spectra, medical treatment and a large proportion of 
our genetic makeup. We also share a common environment. Dogs live, 
unlike more traditional model organisms such as mouse and rat, close to 
humans and often share their indoor environment as well as exercise and 
food habits with their fellow humans. Certainly, the dog offers the research 
community unique opportunities as a model organism for mapping both 
Mendelian and complex diseases.  
 
Autoimmune thyroid disease  
Autoimmune thyroid disease and lymphocytic infiltration of the thyroid 
gland can result in two opposite clinical manifestations, in humans referred 
to as Hashimoto’s disease and Grave’s disease. In the former, lymphocytic 
infiltration in the thyroid leads to apoptosis and hypothyroidism, while in the 
latter it leads to stimulation of thyroid hormone production and 
hyperthyroidism. Hyperthyroidism, or Grave’s disease, is common in humans 
(Wang & Crapo, 1997) while extremely rare in dogs. Therefore this thesis 
focuses on hypothyroidism although at times referring also to Grave’s 
disease, as the two diseases in humans share some common genetic 
background (reviewed in(Tomer, 2010a). 
  
Hypothyroidism in humans and dogs 
The Japanese specialist Hashimoto Hakuru first described human 
autoimmune hypothyroidism in 1912. The disease was named Hashimoto’s 
thyroiditis and was the first autoimmune disease ever to be described. 
Today, it is one of the most common autoimmune diseases (Jacobson et al., 
1997) affecting up to 2% of the general population (Wang & Crapo, 1997) 
and women ten times more frequently than men (Tunbridge & 
Vanderpump, 2000). The occurrence of canine lymphocytic thyroiditis 
(CLT) and its striking similarities to human Hashimoto’s disease was first 
described in a purebred colony of Beagle dogs in 1968 (Beierwaltes & 
Nishiyama, 1968). Since then, the disease has been extensively reported in   15
different breeds and is now considered to be one of the most common 
endocrine diseases also in dog. 
As in human, CLT is characterized by the presence of activated T-
lymphocytes and thyroidal infiltration of lymphocytes, plasma cells and 
macrophages (Gosselin et al., 1982), leading to an acute loss of thyroid 
follicular cells and eventually inability to produce sufficient amounts of the 
thyroid hormones triiodinethyronine (T3) and thyroxine (T4). As the thyroid 
hormone titers decrease, overt hypothyroidism arises and clinical symptoms 
start to appear. The thyroid hormones are crucial for maintaining a normal 
body metabolism, therefore symptoms of hypothyroidism can be widely 
variable and in both human and dog include metabolic (weight gain, 
exercise intolerance, weakness, cold intolerance), dermatologic (hair loss, 
dry skin) and psychological (lethargy, depression) alterations (Mussig et al., 
2012; Burman & McKinley-Grant, 2006; Ai et al., 2003; Dixon et al., 
1999). In dogs, common clinical signs include lethargy, obesity, hair loss and 
poor coat quality (Dixon et al., 1999) (Figure 2). 
 
Figure 2. Pictures of the same CLT-affected hovawart dog, before (left) and after (left) 
medical treatment. Note poor coat quality, lethargic appearance, less bright markings and 
weight gain in the untreated dog (left). Photo: Dr Elisabeth Dietchi.  
 
 
The clinical diagnosis of both human and canine hypothyroidism is 
commonly based on the presence of appropriate clinical signs as well as 
increased serum concentrations of thyroid stimulating hormone (TSH) and 
decreased T4 concentration. Moreover, circulating autoantibodies to specific 
thyroid antigens are present during the course of disease progression. Today, 
no cure or modifying drug for autoimmune hypothyroidism exist, thus both 
human and canine patients are dependent on life-long L-thyroxine 
substitution therapy.  
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Canine lymphocytic thyroiditis; a model for Hashimoto’s disease 
CLT etiology, clinical signs and disease progression perfectly mimic human 
Hashimoto’s disease. The disease develops spontaneously and in high 
frequency. As a consequence of low genetic variation and breeding within 
closed populations discussed earlier, the genetic risk factors for CLT have 
been enriched in certain breeds, theoretically offering a more simple and 
straightforward mapping strategy than in human. Studies from USA report 
high incidence of hypothyroidism in a variety of breeds, such as Doberman 
pinchers, Great Danes, poodles, Irish setters, miniature schnauzers, boxers, 
golden retrievers, dachshunds, Shetland sheepdogs, Pomeranians, cocker 
spaniels and Airedale terriers (Milne & Hayes, 1981; Nesbitt et al., 1980). In 
Sweden, veterinary care insurance data have indicated the highest 
prevalence of CLT in giant schnauzer and hovawart, but also golden 
retriever, Doberman pincher, American cocker spaniel, boxer and 
Rhodesian Rigeback have a higher than average CLT-prevalence (Egenvall 
et al., 2000) suggesting these breeds to be excellent study populations. 
Although many similarities, also some differences exist between the 
human and canine form of autoimmune hypothyroidism. In human, the 
disease is ten times more frequent in women than men (Tunbridge & 
Vanderpump, 2000), whilst neither sex nor neutering status have been 
observed to influence CLT prevalence in the dog (Dixon et al., 1999; 
Beierwaltes & Nishiyama, 1968). Also, in human two major antigens are 
prevalent; thyroglobulin (Tg) and thyroperoxidase (TPO). Both proteins 
play key roles in thyroid hormone synthesis; Tg as the precursor of thyroid 
hormones and TPO as the enzyme catalyzing iodination of Tg‐associated 
tyrosine. In dogs, the major CLT antigen is Tg (Graham et al., 2007), 
although autoantibodies to TPO  can also be found (Skopek et al., 2006). 
 
 
Hypothyroidism in other animal models   
Several rodent models for autoimmune hypothyroidism exist. Some models, 
like the non-obese diabetic mouse (NOD mouse) and the 
BioBreeding/Worcester rat (BB/W rat) develop the disease spontaneously 
(Bernard et al., 1992; Yanagisawa et al., 1986), whereas in others, e.g. the 
severe combined immunodeficiency mouse (SCID mouse) and the nude 
mouse, the disease requires inducement by injection of autoantigens (i.e 
thyroglobulin) (reviewed in(Volpe et al., 1993).  
A domestic animal model extensively used for the study of spontaneous 
autoimmune disease is the Obese strain (OS) chicken, developed at Cornell   17
University by R.K. Cole (Cole, 1966). Cole noticed that about 1% of 
females of the Cornell Special strain (CS) showed symptoms of spontaneous 
autoimmune thyroiditis and started to selectively breed from them. Today, 
after many decades of selective breeding, the strain shows a nearly 100% 
incidence of spontaneous autoimmune thyroiditis (SAT), independent of 
sex. The systematic selection for the SAT phenotype is thought to have 
resulted in homozygosity within the disease-causing loci. Symptoms of SAT 
include small body size and high body weight, long silky feathers and small 
comb (Figure 3). Many studies of the OS chicken have focused on the 
immunology and pathology of SAT (reviewed in(Wick et al., 2006), but  
ongoing efforts at Uppsala University involves studies also of the genetic 
background of the disease (personal communication, Dr. Susanne Kerje). 
 
Figure 3. An obese strain (OS) chicken (left) showing typical signs of hypothyroidism: small 
size, small comb, long silky feathers and subcutaneous and abdominal fat deposits (therefore 
referred to as ‘‘obese’’). To the right, a healthy white leghorn chicken. Photo: Dr Susanne 
Kerje.  
 
Genetics of autoimmune thyroid disease 
Today, there is abundant evidence for a strong genetic background of AITD 
both in human and dog. Early reports of familiar occurrence of both Grave’s 
and Hashimoto’s disease date back almost half a century (Hall & Stanbury, 
1967). More recent studies have shown that over 30% of patients with 
Graves’ or Hashimoto’s disease have a family history of AITD (Villanueva et 
al., 2003). Several twin studies have also reported a higher concordance rate 
in monozygotic twins compared to dizygotic twins for both Grave’s disease   18
and Hashimoto’s disease, further highlighting the genetic importance of 
disease susceptibility (Brix et al., 2001; Brix et al., 2000).  
In dogs, the first report of familial thyroiditis was described in 1968, in a 
breeding colony of beagle dogs (Beierwaltes & Nishiyama, 1968) later 
followed by a study in a family of borzoi dogs (Conaway et al., 1985). 
Furthermore, the fact that prevalence of CLT differs substantially between 
breeds, strongly supports a genetic background of the disease also in dog 
(Milne & Hayes, 1981; Nesbitt et al., 1980). 
 
Human AITD susceptibility genes  
The strong epidemiologic evidence for a genetic background to AITDs has 
encouraged investigators to identify and characterize AITD susceptibility 
genes by use of linkage-, candidate gene- and more recently, whole genome 
association analysis. To date, three immune regulatory and two thyroid 
specific genes have been reported to have an effect on human AITD. Most 
susceptibility genes are common to both diseases, while some are specific for 
Grave’s disease. However, to date, no genes specific for Hashimoto’s disease 
have been reported. 
 
General immune-regulatory genes 
The first locus to be linked to human AITD susceptibility was the major 
histocompatibility complex (MHC), which encodes the human leukocyte 
antigen (HLA) proteins. They are cell-surface antigen-presenting proteins, 
thus playing a key role in immune response activation. The HLA region is 
highly polymorphic and several haplotypes have been associated with AITD 
susceptibility in humans. The strongest association reported has been to the 
HLA-DRB1*0301 allele at the DRB1 locus and an increased frequency of 
the HLA-DR3 haplotype which carries the DRB1*0301 allele have been 
reported in both Grave’s and Hashimoto’s disease patients (Levin et al., 
2004; Zamani et al., 2000; Moens et al., 1978). These studies have been 
further supported by studies in transgenic mice expressing either HLA-
DRB1*0301 or DRB1*0201 and immunized with both human or mouse 
thyroglobulin (Tg). Only DRB1*0301 transgenic mice developed severe 
thyroiditis, providing strong evidence for DRB1 polymorphism as a genetic 
risk factor for thyroiditis (Kong et al., 1996). Additionally, HLA-DR5 and 
DQB1*0301 have been linked to Hashimoto’s disease (Wu et al., 1994; 
Farid et al., 1981). Recently, sequencing of the HLA-DRB1 gene and 
structural modeling studies of the antigen binding pockets identified a   19
specific molecular structure to be strongly associated to both AITD and 
type1 diabetes. An arginine at position 74 in the HLA-DR1 chain resulted 
in a unique pocket structure with a stronger binding to the antigen 
(Menconi et al., 2010).  
Another gene predisposing to general thyroid autoimmunity rather than 
to one specific disease, is the cytotoxic T lymphocyte antigen-4 (CTLA-4). 
The association of CTLA-4 to Grave’s disease has been consistent over 
different ethnic groups, such as Caucasians (Allahabadia et al., 2001; Kotsa et 
al., 1997; Yanagawa et al., 1995), Japanese (Akamizu et al., 2000), Chinese 
(Yanagawa et al., 1995) and Koreans (Marron et al., 1997) and to 
Hashimoto´s disease in Caucasians (Kotsa et al., 1997) and Japanese 
(Akamizu et al., 2000). A more recent study reported that the G allele of the 
CTLA-4 A/G49 SNP is associated with decreased function of CTLA-4, and 
thus an impaired inhibitory effect of CTLA-4 on T-cell proliferation (Ban et 
al., 2003a). The CTLA-4 gene has also been linked to two additional 
autoimmune disorders in human; Addison’s disease (Donner et al., 1997a) 
and type 1 diabetes (Donner et al., 1997b), suggesting that CTLA-4 
polymorphism induces a general susceptibility to autoimmunity (Kristiansen 
et al., 2000). 
Another negative regulator of T-cell activation implicated in human 
organ specific and systemic autoimmune disease is the lymphoid-specific 
phosphatase (Lyp), encoded by the protein tyrosine phosphatase nonreceptor 
22 gene (PTPN22). A SNP in this gene, changing a cytosine residue into a 
thymine at position 1858, inhibits the protein’s ability to suppress T-cell 
activation and was first found to be associated to type 1 diabetes in human 
(Bottini et al., 2004). Since then, the same allele has also been associated 
with both types of AITDs (Criswell et al., 2005; Velaga et al., 2004), familial 
systemic lupus erythematosus (SLE) (Kaufman et al., 2006; Kyogoku et al., 
2004) and rheumatoid arthritis (Begovich et al., 2004).  
Apart from the three genes mentioned above, all representing a shared 
susceptibility to Grave’s and Hashimoto’s disease, one additional immune 
regulatory gene specific to Grave’s disease has been identified; the CD40 
gene (Tomer et al., 2002a). This gene encodes a B-cell surface receptor 
involved in activation of antigen presenting cells. 
 
Thyroid specific genes 
Thyroglobulin (Tg) is a protein produced by the thyroid epithelial cells, and 
serves as a precursor and storehouse of thyroxine (T4) and triiodothyronine 
(T3). Also, thyroglobulin is one of the major autoantigens of human AITDs   20
and therefore represents an appealing candidate gene for both Grave’s and 
Hashimoto’s disease. Indeed, two separate linkage analyses confirmed a 
strong association between the Tg-locus and familial AITDs (Tomer et al., 
2002b; Sakai et al., 2001). Later, this association was confirmed and 
strengthened in both human and murine studies (Ban et al., 2003b).  
A characteristic and specific feature of Grave’s disease is the production 
of autoantibodies to the thyroid stimulating hormone receptor (TSHR). 
Dechario and colleges identified TSHR as a disease-specific susceptibility 
gene for Grave’s disease (Dechairo et al., 2005).  
 
Canine AITD susceptibility genes 
In dog, the only known genetic risk factor associated to hypothyroidism 
disease susceptibility is the dog leukocyte antigen class II (DLA II), the dog 
equivalent to human leukocyte antigen (HLA) class II. In 2006, Kennedy 
and colleagues identified and reported a DLA haplotype in Doberman 
pincher dogs, DLA-DRB1*01201/DQA1*00101/DQB1*00201, to be 
almost twice as frequent in affected dogs compared to unaffected dogs. They 
also suggested it to be a rare haplotype and supposed it unlikely to be 
associated with hypothyroid disease in other breeds (Kennedy et al., 2006a). 
However, the same investigators later reported association to CLT also in 
Rhodesian ridgebacks and English setters carrying the same DQA1 allele 
(DQA1*00101). Notably, CLT affected boxers included in that study did 
not have an increased frequency of DQA1*00101, suggesting different DLA 
class II susceptibility alleles/haplotypes in different breeds (Kennedy et al., 
2006b).  DLA class II polymorphism as a genetic risk factor for CLT will be 
further discussed in paper II of this thesis. 
 
Environmental risk factors 
The identification of several AITD susceptibility genes shows the relevance 
of genetic components of both Hashimoto’s and Grave’s disease in humans, 
as well as for CLT in dogs. Nevertheless, studies in human report 
concordance rates of monozygotic twins well below 1 (Brix et al., 2001; 
Brix et al., 2000), suggesting an important role also for environmental risk 
factors. Through studies of monozygotic twins it has been calculated that 
79% of the susceptibility to develop Grave’s disease is attributable to genetic 
factors, leaving the remaining 21% to be explained by environmental factors 
(Brix et al., 2001).    21
Indeed, several environmental risk factors have been identified in human 
AITD patients. The major environmental triggers include pregnancy, 
medications, stress, smoking, iodine intake, selenium deficiency as well as 
viral and bacterial infections (reviewed in(Prummel et al., 2004). Here we 
will focus on three of the most well documented environmental triggers of 
AITD; iodine intake, interferon alpha  treatment and hepatitis C virus 
infection.  
 
Iodine intake 
Iodine is necessary for thyroid hormone production. Thus the impact of 
iodine intake on human thyroid function has been extensively reported. 
The general belief has long been that severe to moderate iodine deficiency 
may induce hypothyroidism (Hetzel, 1987) and that excessive iodine intake 
is well tolerated without any apparent side effects (Pennington, 1990). 
However, more recent studies have concluded that the association between 
iodine intake of a population and the occurrence of thyroid diseases is U-
shaped, with an increased risk from low as well as high iodine intake (Bulow 
Pedersen et al., 2002).  
Iodine induced hypothyroidism in genetically susceptible animal strains 
have also been investigated. In the autoimmune prone non-obese mouse 
strain (NOD)-H2
h4  5% of individuals develop hypothyroidism 
spontaneously. However, if excessive iodine is added to the drinking water 
more than 60% of individuals develop the disease (Rasooly et al., 1996). In 
dogs, Castillo and colleagues reported a highly significant increase of serum 
TSH together with decrease of free T4 in puppies fed a high iodine diet, 
compared to puppies fed a normal control diet (Castillo et al., 2001). The 
same investigators also report a large difference of iodine content in 
commercial dog feeds, and suggest that dogs fed a high iodine commercial 
diet may develop hypothyroidism.  
 
Interferon alpha treatment 
Interferons are a group of distinct proteins that possess antiviral and 
antitumoral activity. They belong to the large family of cytokines and are 
released by host cells in the presence of pathogens such as virus, bacteria, 
parasites or tumor cells. Their function is to trigger inflammatory and 
antiviral responses by activating immune cells (i.e macrophages and natural 
killer cells) and up-regulate antigen presentation to T lymphocytes.    22
Interferons are divided into two major subgroups; type I and type II. 
Interferon alpha (IFN-) is a type I interferon widely used as a treatment 
against hepatitis C virus (HCV) infection in human (reviewed in(Deutsch & 
Hadziyannis, 2008). Indeed, it is successful; remission of HCV occurs in 
nearly 50% of patients given a combination of IFN- and ribavirin (another 
anti-viral drug)(Fried et al., 2002). However, interferon treatment is also 
associated with many side effects of which interferon induced thyroiditis 
(IIT) is among the most common (Prummel & Laurberg, 2003). Studies 
have shown that up to 40% of IFN- treated HCV patients develop thyroid 
autoantibodies and up to 15% develop clinical hypothyroidism (reviewed 
in(Tomer et al., 2007), suggesting that pharmacological doses of IFN- may 
induce a general activation of the immune system and trigger autoimmunity. 
However within the IFN- treated HCV patient group, non-autoimmune 
thyroiditis is as commonly reported as autoimmune thyroiditis (Tomer, 
2010b). These findings suggest also a direct effect of IFN- on thyrocytes 
and encouraged Mandac and colleagues to propose a new classification of 
IIT; autoimmune IIT and non-autoimmune IIT (Mandac et al., 2006). The 
direct effect of IFN- on thyrocytes was further supported by Caraccio et al 
who reported a significantly decreased expression of key enzymes involved 
in iodine uptake and thyroid hormone production when IFN- was 
cultured with human thyroid follicular cells (Caraccio et al., 2005).  Also, a 
recent study reports that IFN-α treatment of cultured thyrocytes increased 
the expression of Tg, TSHR and TPO, also up-regulating antigen 
presentation and cytokine pathways, as well as increased thyrocyte apoptosis 
(Akeno et al., 2011). This suggests a direct toxic effect of type I interferon 
on the thyroid, as a complementary mechanism to the immune effects. 
To summarize, the strong association between IFN- and thyroid disease 
points out IFN- as one of the environmental factors capable of triggering 
the onset of AITD in genetically susceptible individuals. Furthermore, high 
endogenous IFN- levels may also trigger naturally occurring thyroiditis 
(Prummel & Laurberg, 2003). 
 
Hepatitis C virus infection 
Although a number of viral and bacterial infections have been implicated in 
the pathogenesis of human AITDs (reviewed in(Eschler et al., 2011; 
Desailloud & Hober, 2009; Tomer & Davies, 1993) perhaps the most 
extensively investigated is hepatitis C virus infection (HCV). Studies have 
shown that presence of thyroid autoantibodies is significantly more frequent 
in patients with HCV infection compared to controls, also in patients not   23
receiving IFN- treatment (Tran et al., 1993). In a large study of 630 
chronic HCV patients it was reported that both hypothyroidism and thyroid 
autoimmunity were more common in HCV patients compared to controls, 
even in the absence of IFN- (Antonelli et al., 2004). Further, HCV RNA 
can be detected in the thyroid  glands of patients having chronic HCV 
infection  (Bartolome  et al., 2008). Also, it has been shown that HCV 
proteins are able to bind to thyroid cells and up-regulate secretion of the 
pro-inflammatory cytokine IL-8 (Akeno et al., 2008).  
No closely related animal homolog to the human HCV virus has been 
identified until just recently, when Kapoor and colleagues reported the 
discovery of a novel hepatitis C virus in dogs, the CHV. Comparative 
phylogenetic analyses of CHV showed that it is the most genetically similar 
animal virus homolog of HCV. Interestingly, the estimated divergence time 
of HCV and CHV was only 500-1000 years, well after the domestication of 
the dog, suggesting a potential zoonotic origin of the virus (Kapoor et al., 
2011).  Although the distribution of CHV in the over all dog population is 
currently not known, it will be exciting to see if future studies will find an 
association also between CHV and CLT. 
Two main hypothesis regarding potential mechanisms in which infection 
induces AITDs exists; the molecular mimicry (Wucherpfennig, 2001) and 
the by-stander activation theory. While the first hypothesis proposes that the 
pathogen expresses a part of a protein mimicking self antigens (i.e Tg), 
causing a cross-activation of auto-reactive T- or B-cells, the latter suggests 
that infection of certain tissues induces local inflammation through cytokine 
secretion, and in that way activates T-cells.  
A theoretical consequence of a virus ability to induce autoimmunity is 
the potential triggering effect of vaccination. Indeed, this theory has been 
extensively claimed and counter claimed in the literature (reviewed 
in(Wraith et al., 2003).  Also in the dog, vaccinations have been argued as a 
potential trigger of autoimmune thyroid disease. Scott-Moncrieff 
investigated whether routine vaccination induced antibodies against 
thyroglobulin in dogs, by vaccinating five dogs with a multivalent vaccine 
and a rabies vaccine, five dogs only with rabies vaccine and compared with 
five dogs that were not vaccinated. A significant increase of TgAA was seen 
in rabies-vaccinated dogs, compared with control dogs (Scott-Moncrieff et 
al., 2002). However, in a follow up study in which also postmortem 
examination of the thyroid glands were performed, the investigators failed to 
find any association between vaccination and thyroiditis, since the highest 
rate of thyroiditis (3 of 5 dogs) was actually found in the control group 
(Scott-Moncrieff et al., 2006).    24
Current breeding strategies for CLT and advantages of 
susceptibility gene identification  
Today, few breed clubs have adopted breeding strategies to reduce CLT 
prevalence within the breed. To simply avoid affected animals and their 
close relatives in breeding have not been effective in reducing disease 
prevalence. Therefore, identifying susceptibility gene variants for CLT 
would benefit affected dogs and responsible dog breeders. Such new 
knowledge might lead to the development of a genetic test to use as a 
breeding tool in order to reduce CLT prevalence, as a complement to 
present diagnostic tools to get an earlier diagnose, or to guide treatment 
based on genetic makeup. Further, identification of the genetic background 
of CLT would enable us to better understand the disease mechanism behind 
CLT and therefore, develop better treatment strategies.  
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Aims of the thesis 
The overall aim of this thesis was to;  
 
Unravel the genetic background of lymphocytic thyroiditis in dogs and 
increase the knowledge about its relevance to human Hashimoto’s disease. 
 
The specific aims were to; 
 
I.   Evaluate the diagnostic criteria and estimate the prevalence of CLT in 
two dog breeds, previously indicated as high-risk breeds. 
II.  Investigate DLA class II as a potential genetic risk factor for CLT. 
III. Identify additional genetic risk loci for CLT using whole genome 
association mapping. 
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Summary of Present Studies 
 
Material and Methods 
In this section, a brief description of material and methods used in paper  
I-III is presented. 
Subject recruitment and sampling procedures 
All dogs included in paper I-III were privately owned pet dogs. Through 
access to the Swedish Kennel Club (SKC) registry, potential study subjects 
were selected based on breed and age. Owners were contacted through mail 
and were invited to have their dog included in the study. Also, a website 
describing CLT, common clinical symptoms, disease progression and 
sampling procedures was produced in order to facilitate information to dog 
owners and veterinarians. Information about the study and further 
recruitment of subjects was also achieved by visiting breed club meetings, 
dog competitions and dog shows. A close cooperation with veterinarians, 
the SKC doping commission and the Swedish University Animal Hospital 
laboratory also enabled targeted sampling of dogs previously diagnosed as 
CLT-affected. All dogs were purebreds belonging to the Scandinavian 
population, with the exception of a few importees. 
For all dogs, EDTA-blood and serum samples were collected. Trained 
clinicians or veterinarians collected all samples after owners consent, 
following ethical approval protocols (Dnr C139/9, Ethical board for 
experimental animals in Uppsala, Sweden). Accompanying all samples were 
a dog-owner questionnaire surveying clinical status and environmental 
factors potentially influencing dog disease status, as well as registration 
number and phenotypic information. DNA was extracted using QIAamp   28
DNA Blood Mini/Midi Kit or QiaSymphony DNA midikit (Qiagen, 
Valencia, CA).  
 
Dog material 
Blood and sera from 600 giant schnauzer and 255 hovawart dogs were 
collected between 1999 and 2012. Also, a number of individuals from three 
additional breeds; Welsh springer spaniel (WSS), boxer and Polish lowland 
dog (PLD) were sampled (Table 1). 
 
Table 1. Total number of collected samples within different breeds. 
Breed  Blood and sera samples  Classified as cases   Classified as controls 
Giant Sch.  597  142  102 
Hovawart 255  47  87 
WSS 50  15  10 
Boxer 15  10  2 
PLD 43  18  12 
WSS Welsh springer spaniel, PLD Polish lowland dog. 
 
Diagnostic criteria and phenotypic characterization (paper I-III) 
Inclusion criteria for cases and controls were based on serological 
measurements of thyroid stimulating hormone (TSH), free thyroxine (fT4) 
and autoantibodies to thyroglobulin (TgAA). Concentration of TSH was 
measured by using a commercially available immunoradiometric assay kit 
(Diagnostic Products Corporation, Los Angeles, CA, USA) previously 
validated for canine serum samples (Paradis et al., 2003). TgAA were assessed 
using ELISA following the manufacturers’ instructions  (Oxford Biomedical 
Research) and using the same diagnostic cutoff as previously defined 
(Nachreiner et al., 1998). 
Dogs were classified into three different categories as follows; cases, 
borderline cases and controls, as shown in Table 2.  
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Table 2. Diagnostic criteria for cases, borderline cases and controls. 
 Case  Borderline  case  Control 
TSH (mU/L)  ≥40  40 < TSH ≥ 30   ≤ 25 
TgAA (%)  ≥200  200 < TgAA ≥150  ≤ 100 
fT4 (pmol/l)      5-25 
Age (years)      ≥ 7 
TSH thyroid stimulating hormone, TgAA autoantibodies to thyroglobulin, fT4 free 
thyroxine. 
 
Estimation of CLT prevalence (Paper I) 
To evaluate the prevalence of canine lymphocytic thyroiditis (CLT) in the 
Swedish populations of giant schnauzer and hovawart dogs and to study 
disease progression within these breeds, paper I was performed as a birth 
cohort study including only 3-4 and 6-7 year old dogs, respectively. In total 
236 giant schnauzers (3-4 years n=105, 6-7 years n=131) and 95 hovawarts 
(3-4 year n=47, 6-7 years n=48) participated. CLT status was investigated 
through serological screening of TSH and TgAA as described previously. 
Dogs with TSH serum levels ≥40mU/L and/or TgAA serum levels ≥200% 
of the negative control were considered CLT-affected (Table 2). 
 
Identification of CLT risk loci (Paper II and III) 
DLA sequencing  
Using a candidate gene approach, paper II was designed to evaluate MHC 
class II genotype as a predisposing genetic risk factor for development of 
CLT in giant schnauzer dogs. A comparative sequence analysis of the entire 
polymorphic exon 2 of DLA-DRB1, -DQA1 and -DQB1 was performed in 
30 controls, 74 cases and 28 borderline cases, using flanking intronic and 
locus-specific primers. For comparative purposes, 48 hovawarts (cases, 
n=23, controls n=20, borderline case n=5) were also sequenced. After PCR 
amplification and subsequent sequencing, the obtained sequences were 
matched to a reference sequence library to provide the matching DLA allele. 
Odds ratios, risk ratios, confidence interval and p-values for each allele and 
haplotype were calculated using χ
2 test.  
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Genome-wide association analysis 
In order to identify novel susceptibility loci for CLT, paper III was designed 
as a genome-wide association study, using the canine high density SNPchip 
(Illumina) comprising more than 174,000 evenly spaced and validated SNPs 
(Vaysse et al., 2011). In total, 122 giant schnauzers unrelated at parental level 
and strictly classified as cases (n=74) and controls (n=48) were included in 
the sample set. PLINK software (Purcell et al., 2007) was used to perform a 
standard case-control analysis as well as assess genomic inflation and 
population stratification. After frequency and genotype pruning (call rate 
>75%) 117,064 SNPs and all 122 individuals were included in subsequent 
analysis. The final dataset was shown to be non-stratified using a QQ-plot 
(=1.03), where the observed values deviate from expected values at a -logp 
of 4.0. This was therefore used as a significance threshold.  
 
Targeted re-sequencing 
To further investigate the associated regions and to search for causative 
mutations, a 385 K custom-designed sequence capture array from Roche 
NimbleGen was used for targeted re-sequencing of nine giant schnauzer 
dogs classified and selected based on phenotype (case n=3, control n=3) as 
well as genotype (homozygous risk n=7, homozygous control n=1, 
heterozygous n=1). In total 4.1 Mb on chromosome 11 (position 
39,000,000 - 41,000,000 and 42,600,000 - 44,7000,000) was targeted. The 
obtained sequences were aligned to CamFam2.0 (Lindblad-Toh et al., 2005) 
using Burrows-Wheeler Alignment Tool (BWA) (Li & Durbin, 2009).  
 
SNP- and indel detection 
SNP-calling was performed using SAMtools (Li et al., 2009). To investigate 
putative insertions, deletions or copy number variants differing between 
dogs carrying the risk versus control haplotype, we used Seqscoring (Truve 
et al., 2011) to calculate the ratio between average coverage in dogs carrying 
risk versus control haplotype. Seqscoring software (Truve et al., 2011) using 
the SiPhy (Garber et al., 2009) 29 mammals conservation set (Lindblad-Toh 
et al., 2011) was also utilized to score SNPs according to their degree of 
conservation. SNPs located within or maximum 5 bp away from a 
conserved element were selected for further genotyping in a larger sample 
set. Genotyping was performed using a custom designed VeraCode 
GoldenGate assay (Illumina).  
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Homozygosity and association to litter size  
Based on the oscillating association on chromosome 11 we wanted to 
examine the region for evidence of a selective sweep. By searching for 
regions of reduced heterozygosity we revealed a 291 kb region of heavily 
reduced heterozygosity (minor allele frequency, MAF = 0-0.02) at position 
40,091,793-40,382,938 bp. This region of reduced heterozygosity covers 
the first half of the gene encoding centlein (CNTLN), a centrosomal protein 
important for meiosis (Makino et al., 2008). In order to investigate whether 
this potential sweep signal is specific for giant schnauzers or exists also in 
other breeds, we examined the degree of heterozygosity in the surrounding 
genomic region (chromosome 11 position 39-41 Mb) in a number of other 
breeds using genotype data from the 170 k Illumina SNP array (Vaysse et al., 
2011). It was shown that hovawart, English setter and weimaraner showed a 
similar pattern of reduced heterozygosity over the CNTLN gene. Another 
long region of reduced heterozygosity  (30 kb) covering most of the BNC2 
gene at position 39,540,307-39,930,544 bp was identified in German 
shepherd, Dalmatian and Brittany spaniel. Breeds being heterozygous over 
the region were Border collie, Golden retriever, Eurasier, Irish wolfhound, 
Rottweiler, shar-pei and Greenland sledge dog.  
Since the reduced heterozygosity was found in many breeds, we 
hypothesized that selection was being employed for more generally desirable 
factors, generating selective sweeps in many breeds. Such selection could 
potentially explain the high frequency of thyroiditis observed in many 
breeds. We hypothesized that selection for a large litter size might be 
common. This hypothesis was also attractive based on the biological 
influence of centlein during meiosis (Makino et al., 2008), and the presence 
of several genes expressed in ovary and uterus in this region. Using the 
Swedish Kennel club registration data for all births, we examined the mean 
litter size for 14 breeds (all breeds examined were large or medium sized 
breeds as litter sizes in small dogs are generally lower than in large dog 
breeds) for 22 consecutive years and calculated an overall mean litter size per 
breed. Breeds were then grouped based on the presence of BNC2- (giant 
schnauzer, hovawart, English setter, Weimaraner) or CNTLN sweeps 
(German shepherd, Dalmatian and Brittany Spaniel) or for being 
heterozygous across the region (Border collie, Golden retriever, Eurasier, 
Irish wolfhound, Rottweiler, shar-pei and Greenland sledge dog). As a 
secondary test we examined the fraction of dogs within each of 14 breeds 
that carried at least one copy of the ‘selected’ haplotype. We then performed 
a correlation between this fraction and the overall mean litter size per breed.    32
 
Main findings 
In this section, a brief description of obtained results from paper I-III is 
presented.  
 
High prevalence of CLT in giant schnauzer and hovawart dogs (paper I) 
In paper I we identified an extraordinarily high prevalence of CLT in giant 
schnauzer and hovawart dogs, suggesting a strong genetic predisposition to 
CLT within these breeds. In total, 16% of giant schnauzers and 13% of 
hovawarts had indications of CLT, with or without clinical signs of 
hypothyroidism. As expected, CLT prevalence was higher in the older 
cohort (6-7 years) than in the young cohort (3-4 years) where only a few 
individuals had showed any clinical signs of CLT or received a CLT 
diagnosis at the time of sampling (Figure 4). However, measurement of 
serum TSH and TgAA in this young group revealed signs of CLT (positive 
TgAA or increased TSH) in more than 10 % of dogs, suggesting a high 
prevalence of subclinical CLT within the age group where most breeding 
dogs are being used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Prevalence of CLT within different breed and age categories. Dark blue bars 
represent the percentage of dogs already diagnosed with CLT at the indicated age; i.e cases of 
overt hypothyroidism, while light-blue bars indicate the proportion of dogs with subclinical 
CLT. The total length of the bars represents the total prevalence of CLT (with and without 
clinical signs) within each breed and age group.  
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Identification of risk- and protective DLA-haplotypes (paper II) 
In paper II we obtained evidence that DLA class II polymorphism can 
function both as a genetic risk factor predisposing to the disease, and as a 
protective factor against the disease. In total eight DRB1 alleles, four DQA1 
alleles and six DQB1 alleles, organized into nine different haplotypes were 
identified in the giant schnauzer. The frequencies of two specific haplotypes 
differed markedly between cases and controls. The DLA-DRB1*01201/ 
DQA1*00101/DQB1*00201 haplotype was found in 18.2% of cases, while 
only in 3.3 % of controls and the DLA-DRB1*01301/ DQA1*00301/ 
DQB1*00501 haplotype was found in 35.0% of controls while only in 
15.5% of cases (Table 3). Odds ratios for the risk and protective haplotypes 
were 6.5 (99% CI 1.0-194) and 0.3 (99% CI 0.14-0.85) respectively, and if 
including borderline cases, the OR for the risk haplotype increased to 6.6.  
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Table 3. DLA-DRB1, -DQA1 and -DQB1 haplotype frequencies among all giant schnauzer 
samples, and for the study population (cases and controls). Bold numbers indicate significant 
differences between cases and controls. 
a Two chromosomes per individual 
 
When comparing allele frequencies separately, we observed a higher 
frequency in CLT cases compared to controls for all three alleles found in 
the risk haplotype. However, DRB1*01201 was exclusively carried on the 
risk haplotype, while the other two alleles were also present on non-risk 
haplotypes. This indicates that it may be a DRB1 allelic effect, rather than a 
haplotypic effect, causing the increased genetic predisposition in dogs 
carrying the DRB1*01201 allele. In contrast, the protective effect was not 
detected when comparing the three alleles on the protective haplotype 
separately, suggesting that these three alleles act together to obtain a 
protective effect. 
In the hovawart, six DLA-DRB1 alleles were found. The DLA-
DRB1*01201 allele had a total allele frequency of 48%, while the additional 
five alleles were rare or moderately frequent with allele frequencies ranging 
between 1.0-18.4%.  
 
Haplotype 
*DRB1*DQA1*DQB1 
All samples (132 dogs)
% (no
a) 
Cases (74 dogs)
% (no
a) 
Controls (30 dogs) 
% (no
a) 
*00101*00101*00201 25.0  (66)
 
29.1 (43) 20.0 (12) 
 
*01201*00101*00201 15.2  (40)
 
18.2 (27) 3.3 (2) 
 
*00601*00401*01303 17.0  (45)
 
15.5 (23) 20.0 (12) 
 
*01301*00101*00201 7.2  (19)
 
8.8 (13) 6.7 (4) 
 
*01301*00301*00501 22.0  (58)
 
15.5 (23) 35.0 (21) 
 
*02301*00301*00501 8.7  (23)
 
8.1 (12) 8.3 (5) 
 
*00901*00101*008011 2.3  (6)
 
2.0 (3) 3.3 (2) 
 
*01501*00601*02201 1.9  (5)
 
1.4 (2) 3.3 (2) 
 
*02001*00401*01301 0.8  (2)
 
1.4 (2) 0 (0) 
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Strong association to chromosome 11 and X (paper III) 
The genome-wide association analysis identified a strong association to 
chromosome 11 and X, both with raw p-values of 1.5 x 10
-6 (Figure 5). The 
QQ-plot indicated a -- -log (p) value above 4.0 to be genome-wide significant 
at the 5% level. Assessment of the genomic inflation factor indicated very 
limited stratification within our sample set, with a lambda-value of 1.03.  
 
 
 
Figure 5. Genome-wide association analysis of 74 cases and 48 controls identified strong 
susceptibility loci located on chromosome 11 and X. A -logp value of 4.0 were used as a 
threshold for genome-wide significance as indicated by red horizontal lines. 
 
Chromosome X 
The associated region on chromosome X encompassed a 2.3 Mb wide 
region and was separated into peaks within or close to the genes LANCL3, 
XK,  CYBB,  OTC,  TSPAN7 and BCOR, respectively (Figure 6). Four 
SNPs flanking the BCOR gene represented the strongest association within 
the locus (praw= 1.5x10
-6, OR=
  4.3).  BCOR  encodes the protein Co-
repressor of B-cell lymphoma 6. It is a co-repressor of BCL6, an 
evolutionarily conserved zinc-finger protein known to suppress transcription 
of genes involved in inflammation and lymphocyte differentiation (Shaffer et 
al., 2000). Also, a recent study reports that BCL6 and NF-kB (nuclear factor 
kappa-light-chain-enhancer of activated B cells) act as opposite regulators of 
the innate immune response (Barish et al., 2010). Other interesting   36
candidate genes within the chromosome X locus are TSPAN 7 (encoding 
the leukocyte cell surface protein tetraspanin 7) and CYBB (encoding the b-
chain of cytochrome b). Tetraspanins are known to interact with molecules 
of the immune system, such as integrins, immunoreceptors and the major 
histocompability  complex (Tarrant et al., 2003). CYBB is involved in 
microbicidal oxidase in phagocytes (Pollock et al., 1995) and different 
mutations in this gene has previously been linked to chronic granulomatous 
disease (Rabbani et al., 1993; Bolscher et al., 1991; Dinauer et al., 1989; 
Teahan et al., 1987).  
 
Figure 6. The associated region on chromosome X. The most consecutive association, also 
including the strongest SNP (p-value = 1.5 x 10
-6) mapped to the BCOR-gene, known to 
interact with genes important for inflammation and lymphocyte differentiation.  
 
Chromosome 11 
The associated region on chromosome 11 stretched 8.4 Mb (Chr11: 37.36-
45.75 Mb) and was separated into several association peaks (Figure 7). The 
strongest signal came from a single SNP located downstream of FREM1 
(position 38.193.521, praw=1.5x10
-6), a gene with two alternatively spliced 
transcript variants. The shorter transcript, called Toll-like/interleukin-1 
receptor regulator (TILRR), is a co-receptor of the interleukin 1 receptor   37
family and thought to contribute to the control of inflammatory response 
activation through the NF-kB pathway (Zhang et al., 2010). However, the 
largest consecutive signal, represented by ten genome-wide significant 
SNPs, mapped to the flanking regions of BNC2 (basonuclin2). It is an 
extremely conserved zinc-finger protein thought to act as a transcription 
factor (Romano et al., 2004; Vanhoutteghem & Djian, 2004). Interestingly, 
recent data suggests that BNC2 also act as a suppressor of NF-kB activity (Li 
et al., 2011). The interferon alpha genes, represented by a single SNP at 
position 43.807.665 (praw=1.2x10
-5) is also possible candidate genes, since 
high IFN- levels are known to trigger autoimmune thyroid disease both 
through direct effect on the thyrocytes and through immune response 
activation (Mandac et al., 2006). Furthermore, a long intergenic non-coding 
RNA (lincRNA) is located just upstream of BNC2 . LincRNAs are known 
to have an effect on gene expression both through association with 
chromatin-modifying complexes and by recruitment of transcription factors 
(Khalil et al., 2009) and thus are potential regulators of disease development.   38
Figure 7. The associated region on chromosome 11. The strongest signal was to a SNP 
downstream of FREM1, while the most consistent association mapped to the flanking region 
of BNC2. Both genes are known regulators of the NF-kB pathway. 
 
 
Targeted re-sequencing identified >9000 SNPs and a 9.5 kb insertion 
within the targeted region. Currently we are investigating a number of 
SNPs located within the promoter and coding sequences of FREM1, BNC2 
and  CNTLN for allele-specific expression. Also, the large indel 
(insertion/deletion) located within the interferon alpha region, is further 
investigated in a larger sample set. 
 
Homozygozity and a potential connection to litter size  
We identified a drop in minor allele frequency in the close vicinity of our 
strong association on chromosome 11 (Figure 8b). The homozygous region 
was 291 kb and covered most of the gene encoding centlein (CNTLN). A 
similar pattern of homozygosity was also recognized in hovawart, English   39
setter and Weimaraner. A different homozygosity pattern instead covering 
the BNC2 gene was found in German shepherd, Dalmatian and Brittany 
spaniel, while border collie, golden retriever, Eurasier, Irish wolfhound, 
rottweiler and Greenland sledge dog were heterozygous across the region. 
Average litter size was statistically different for all groups, although strongest 
when comparing the heterozygous group to the CNTLN- g r o u p   ( p  <  
0.0001) (Figure 8b-d).  
As a secondary test we examined the fraction of dogs within each of 14 
breeds that had at least one copy of the ‘selected’ haplotype and performed a 
correlation between this fraction and the overall mean litter size per breed. 
An R
2- value of 0.73 was seen. Although being performed in a limited 
material, these observations suggest that selection for increased litter size 
within certain breeds has caused a reduced variation within this region. 
Whether this selection has influenced also CLT susceptibility remains to be 
further investigated.  
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Figure 8. A zoom in on chromosome 11, illustrating the association across BNC2, lincRNA 
and CNTLN (a). Green lines illustrate the minor allele frequency (MAF) in giant schnauzer 
(b), dalmatian (c) and golden retriever (d) across the region.  
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General discussion 
The purpose of this thesis was to estimate the prevalence of canine 
lymphocytic thyroiditis and to gain knowledge about the genetic 
background of the disease. Here the results obtained in paper I-III are 
discussed in a more general perspective.   
 
Prevalence of CLT  
Canine lymphocytic thyroiditis (CLT) is considered to be one of the most 
common endocrine diseases in dog, affecting multiple breeds in high 
frequency. Characteristics for modern dog breeding have long been the use 
of a limited number of breeding dogs, frequent use of popular sires and 
strong selection for desirable traits. This breeding strategy, intended to fix a 
desirable trait within the population, has unfortunately also enriched genetic 
risk factors for specific diseases to the extent that almost all breeds exhibit 
their ‘own’ diseases.  
For diseases that develop late in life, many dogs may have been bred 
prior to disease onset, thereby contributing to the high disease frequency. 
This is in fact the case with CLT, in which clinical signs usually develop 
late. As seen in paper I, few dogs show clinical signs at the age of 3-4 years, 
even though many are affected by subclinical CLT. According to data from 
the Swedish Kennel Club registry, the majority of giant schnauzers are 2-3 
years old when they are first used in breeding, therefore able to produce 
affected offspring before CLT is diagnosed. Based on the results from this 
study we proposed screening of individuals within high-risk breeds prior to 
breeding. Today the Swedish breed club of giant schnauzer dogs has 
adopted this strategy in order to try to reduce CLT prevalence within the 
breed.   42
Insurance data has previously indicated the giant schnauzer and the 
hovawart to be high-risk breeds for the disease (Egenvall et al., 2000), 
showing at least 6 times increased risk compared to the overall Swedish dog 
population. Although providing important epidemiologic information such 
as breed- differences and age distribution, insurance data stands short when 
it comes to estimating CLT prevalence. CLT is not a costly disease to 
diagnose, therefore economic compensation is not usually claimed. 
Consequently, CLT diagnoses registered at the insurance company are 
probably underestimating the true prevalence. In paper I we therefore based 
our prevalence estimation on serological screening of roughly 230 giant 
schnauzers and 100 hovawarts, which should provide a more accurate view. 
Still, our study has limitations. We have sampled only 22-38% of dogs born 
within each birth-cohort. Consequently, this may result in estimation errors. 
Also, a certain degree of relatedness could be seen both within and between 
cohorts.  
 
Consequences of high CLT prevalence within the study cohort 
The high prevalence of CLT within the giant schnauzer breed had 
consequences on sampling strategies for our subsequent genetic studies. 
Even though high disease prevalence should be beneficial when hunting for 
disease-causing alleles, it might have been more straightforward to perform 
the study in a breed showing a slightly lower CLT prevalence, since we 
found it challenging to find enough healthy controls to match our cases. 
Many dogs, believed to be old healthy controls, had to be excluded due to 
increased TSH concentrations. To investigate if the increased TSH was due 
to age rather than genetic risk factors for CLT, we measured TSH, TgAA 
and free T4 concentrations in ten German shepherd dogs, a breed not 
commonly affected with CLT. All dogs were above ten years of age and had 
serum concentrations well within our strict criteria for healthy controls, 
suggesting that increased TSH in older giant schnauzer dogs is not a sign of 
an aging thyroid but rather a sign of forthcoming disease. The high genetic 
predisposition to CLT in giant schnauzers was also well illustrated in paper 
III, by the high frequency of the risk haplotype within our study population. 
Eighty-one percent of cases were homozygous for the risk haplotype across 
FREM1,  BNC2 and INF-, while no cases were homozygous for the 
protective haplotype. The risk haplotype was common also in the control 
group, where 38% of dogs were homozygous. Together, these observations 
explain the extraordinary high prevalence of CLT within the breed, as well 
as the difficulties identifying suitable controls.    43
 
CLT classification 
The classification of cases and controls established in paper I and applied in 
paper I-III proved to be well suitable. Strong genetic risk factors, both the 
DLA and the loci on chromosome 11 and X were identified based on those 
criteria. However, in a bigger sample set and by using a breed showing not 
quite as high CLT prevalence we might have been able to apply even more 
stringent criteria for cases and controls. Also, by analyzing the data divided 
into subsets of different diagnostic characteristics, age at onset, gender etc we 
might have been enabled to assess genetic modifiers and possible gender 
differences.  
DLA- risk and protective haplotype 
In paper II we identified the DLA-DRB1*01201/ DQA1*00101/DQB1 
*00201 haplotype to be a risk factor for CLT, while the DLA-
DRB1*01301/ DQA1*00301/ DQB1*00501 haplotype instead was found 
to have a protective effect against development of the disease. Assessment of 
all the different alleles separately suggested the DLA-DRB1*01201 as a 
major risk allele for CLT development in giant schnauzer dogs. This allele 
has also been correlated with the development of hypothyroid disease in 
Doberman pinchers (Kennedy et al., 2006a). The Swedish giant schnauzer 
population appeared to be moderately genetically diverse with four DRB1 
alleles in relatively high frequencies and with an additional five rare alleles, 
whereas hovawart appears to exhibit lower genetic variation at the MHC.  
The major difference in MHC polymorphism between the giant 
schnauzer and the hovawart was the fact that within the hovawart sample 
set, one specific haplotype, the DLA-DRB1*01201/DQA1*00401/DQB1 
*013017, was present in a frequency of 48%, indicating that hovawart is a 
breed with less divergence within the DLA region, compared to the giant 
schnauzer. This haplotype contains the DLA-DRB1*01201 allele as found 
in the giant schnauzer risk haplotype, potentially explaining the high 
frequency of CLT within the breed. However, these results must be 
interpreted cautiously, since the number of hovawarts in the study was 
rather limited.  
 
As expected, the association to DLA was not identified in the genome wide 
association analysis, but only through the candidate gene approach. This is   44
because the DLA region is extremely polymorphic, and the SNP density of 
the SNPchip is not sufficient to fully explore the genetic variation within 
the DLA region, thus direct sequencing is more efficient.  
 
Genome-wide association analysis 
In paper III, strong susceptibility loci were identified using genome-wide 
association analysis in only 74 cases and 48 controls, even lower than the 
predicted number of individuals needed to map a complex trait (Lindblad-
Toh et al., 2005) but in concordance to other recent studies (Olsson et al., 
2011; Wilbe et al., 2010). This highlights the unique features of the dog 
genome and the great opportunities it offers in the hunt for disease causing 
mutations. The associated region on chromosome 11 was wide, showed 
several signals and harbors a large number of candidate genes, thus making 
interpretation of the association more difficult. Linkage disequilibrium across 
the region is extensive, illustrated by the high proportion of individuals 
(78.6%) showing an un-broken haplotype all the way from FREM1 (at 38.1 
Mb) to IFN- (at 43.8 Mb).  
 
Litter size vs hypothyroidism 
The possible connection between litter size and thyroid autoimmunity 
observed in paper III is somewhat controversial, since hypothyroidism is 
thought to negatively influence reproduction both in human (Matalon et al., 
2001) and dog (Johnston, 1980). On the other hand, thyroid function has 
been reported to be elevated during pregnancy in humans (Krajewski & 
Burman, 2011) and hypothyroidism frequently debut in conjunction with 
pregnancy (reviewed in(Gaberscek & Zaletel, 2011), suggesting a potential 
link between reproduction, increased thyroid activity and an autoimmune 
reaction. The two genes located within the potential sweep, BNC2 and 
CNTLN, both are expressed in uterus. Centlein is a centrosomal protein  
important during meiosis (Makino et al., 2008) and BNC2 have been 
reported to be essential for reproduction in zebrafish (Lang et al., 2009). 
Also in domestic and wild birds, a connection between thyroid 
stimulating hormone (TSH) and reproduction is well known, since the 
TSH-receptor (TSHR) is an established regulator of photoperiod control of 
reproduction in birds. Increased TSH is a known trigger of seasonal 
breeding in birds (Nakao et al., 2008; Yoshimura et al., 2003), suggesting 
that an increased TSH concentration would reduce the strict regulation of   45
seasonal reproduction found in natural populations. Interestingly, recent 
whole genome sequencing of the chicken revealed a selective sweep, 
present in all domestic chickens, within the locus of thyroid stimulating 
hormone receptor (TSHR) (Rubin et al., 2010). Two of the most striking 
differences between the domestic chicken and its ancestor, the red jungle 
fowl, are the absence of seasonal breeding and an extraordinary increased 
egg production. 
Hypothetically, selective breeding for larger litter size in certain breeds of 
dogs might have influenced genes important for thyroid autoimmunity, 
located within the selected haplotype.  
 
FREM1, BNC2 and BCOR and their role in NF-kB pathway 
Although a large number of genes are present in the associated regions 
identified in our genome-wide association study, a striking pattern between 
the most strongly associated genes FREM1, BNC2 (both on chromosome 
11) and BCOR (chromosome X) emerges. Each member of this gene triplet 
is known to have an impact on the NF-kB pathway (nuclear factor kappa-
light-chain-enhancer of activated B cells), which plays an important role in 
the regulation of apoptosis and inflammation as well as innate and adaptive 
immunity. Incorrect regulation of NF-κB has been linked to several 
inflammatory and autoimmune diseases, such as rheumatoid arthritis, 
multiple sclerosis, type1 diabetes, inflammatory bowels disease, SLE and 
AITDs  (reviewed in (Kurylowicz & Nauman, 2008).   
FREM1, the gene located close to the strongest peak of genetic 
association on chromosome 11 (p-value 1.5x10
-6) has two alternative 
transcripts. The shorter transcript is called Toll-like/interleukin-1 receptor 
regulator (TILLR), is highly conserved, widely expressed and functions as 
an enhancer of interleukin 1-regulated inflammatory responses through 
activation of NF-kB and inflammatory genes (Zhang et al., 2010).  
 BNC2, also located within the chromosome 11 region and represented 
by the largest consecutive association, encodes the zinc-finger protein 
basonuclin2, an extremely conserved protein thought to act as a 
transcription factor (Vanhoutteghem & Djian, 2004). In a recent paper, 
BNC2 was also reported to significantly suppress NF-kB activity (Li et al., 
2011). 
BCOR, located within the strongest association on chromosome X, 
encodes a co-repressor of BCL6 (B-cell lymphoma 6) (Huynh et al., 2000). 
BCL-6 has an important function in inflammation (Shaffer et al., 2000) and 
can either promote or inhibit apoptosis (Kurosu et al., 2003; Albagli et al.,   46
1999). Moreover, BCL-6 and NF-kB were recently reported to mediate 
opposite regulation to the innate immune response (Barish et al., 2010). In 
summary, the biological functions of these three genes indicate their 
potential role in a common pathway. Together with the high association 
found to their genomic location, this makes them strong candidate genes for 
the development of thyroid autoimmunity. 
 
The interferon alpha region 
In paper III we also identified a SNP strongly associated to CLT phenotype  
(praw= 1.2x10
-5) at position 43.807.665, within the cluster of interferon alpha 
genes. Resequencing of the region indicated a potential 
insertion/duplication, 9.5 kb in size. If this insertion duplicates IFN- 
regulatory elements, or even entire IFN- genes, it might lead to an 
increased endogenous IFN- concentration and potential susceptibility to 
autoimmune thyroid disease, as discussed earlier. However, working with 
the interferon region in dog has proven to be more challenging than 
expected. First, there seems to be a problem with the genome assembly for 
this region, since canine IFN- genes are aligned to ‘chromosome 
unknown’ (which contains sequences that can not be confidently aligned to 
a specific chromosome). Second, the interferon region is not well annotated 
in the dog, illustrated by interferon genes annotated as genes with introns, 
even though interferon genes are known to be intron-less. Further more, it 
is not possible to measure IFN-a concentrations in dog sera using human 
assays. For regions such as this, it is important to develop better methods to 
assemble and to detect copy number variants as well as annotation strategies, 
e.g. combine mRNA-sequence data from dog with better alignments of 
other species.  
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Conclusions 
Overall, the results of this thesis contribute to an increased knowledge of the 
prevalence and genetic background of canine lymphocytic thyroiditis 
(CLT). It also highlights the advantages of using the dog as a model for 
mapping complex traits. More specifically, the main conclusions are as 
follows: 
 
o  Giant schnauzer and hovawart are extreme high-risk breeds for canine 
lymphocytic thyroiditis (CLT), with an overall prevalence of 16 and 13 
percent in the Swedish populations. Subclinical CLT is prevalent in 3-4 
year old dogs, while overt hypothyroidism is more common in older 
dogs.  
 
o  DLA class II polymorphisms can generate increased risk for CLT, but 
also provide protection against the disease. The DLA-DRB1*01201/ 
DQA1*00101/DQB1*00201 haplotype was shown to be a strong 
genetic risk factor for CLT development in giant schnauzer dogs, 
conferring a 6.5-fold increased risk. On the contrary, the DLA-
DRB1*01301/DQA1*00301/DQB1*00501 haplotype conferred a 
3.3-fold decreased risk for CLT development in giant schnauzers.  
 
o  Additional risk loci for CLT in giant schnauzer are located on 
chromosome 11 and X and include strong candidate genes involved in 
immune regulation and inflammation. The strongest associations were 
identified close to FREM1 and BCOR, both are which are linked to 
Nf-B activation. 
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Future prospects 
Genetic risk factors  
Even though we have made significant progress towards understanding the 
genetic contribution to the etiology of CLT, we still have a long way to go. 
Within the closest future lies the challenge to identify disease-causing 
mutations within the associated regions on chromosome 11 and X. 
Therefore, we are currently expanding the targeted re-sequencing to further 
investigate the associated region on both chromosomes and in additional 
dogs. We are also currently investigating SNPs located within the coding 
sequences and promoter regions of FREM1, BNC2 and CNTLN for allele-
specific expression in different tissues, by examining SNPs in the transcript 
that tag the different alleles. Also, the potential 9.5 kb insertion/deletion 
within the IFN- region needs to be genotyped in a larger sample set.  
Further, a crucial part of the future of this project is the functional 
characterization of the identified candidate mutations. It is important to plan 
these experiments based on the nature of the candidate mutation i.e. coding 
mutation (causing a change in the protein), non-coding mutation (may 
affect expression level or degradation of mRNA) and regulatory mutation in 
elements outside the transcripts (promoters and enhancers/silencers). This 
can be performed by using molecular cell biology techniques such as cell-
cultures, over-expression/silencing of proteins or promoter-assays. The 
functional results should be compared to molecular genetic data derived 
from mRNA sequencing (for instance from lymphocytes and thyroid tissue). 
Furthermore, methods like Chromatin Immunoprecipitation-sequencing 
(Chip-seq), Electrophoretic Mobility Shift Assay (EMSA) etc., would 
provide answers about signaling pathways, transcriptional regulatory 
networks and other proteins involved in disease development. The 
information about functionality of the causative mutations would take us   50
one step closer to the ultimate goal of developing new strategies for 
diagnosing and more effectively treating the disease in both dogs and 
humans.  
Next in the pipeline lies the identification of additional risk loci through 
use of other high-risk breeds for CLT. We have already performed a 
genome-wide association analysis in 30 cases and 30 controls from the 
hovawart breed and identified an association to a novel CLT locus, 
confirmed and strengthened by meta-analysis together with a second breed. 
Re-sequencing of that region is ongoing. If sampling additional breeds, the 
golden retriever with a proposed increased risk of 2.8 (Egenvall et al., 2000) 
and an annual registration number >2000 individuals is an appealing 
candidate breed.  
In parallel to revealing more about the genetic background of CLT and 
the effects of the risk factors to the development of the disease, we are 
planning to use the gained knowledge to reveal comparative information 
relevant for human Hashimoto’s thyroiditis. We have gathered a list of genes 
from the various mapping projects of canine immunological- and immune-
mediated diseases ongoing in our laboratory, as well as genes indicated as 
counterparts in the pathways that canine candidate genes are playing a role 
in and added a selection of genes known to have a role in immune system in 
general. We are planning to re-sequence all the known transcripts of these 
roughly 1500 genes, as well as potential regulatory elements located in the 
non-coding parts of the genes of interest. This strategy is slightly adapted 
from a general and nowadays widely used exome sequencing and we believe 
it is more relevant since most of the causative mutations we expect to be 
regulatory and/or rare variants. 
Environmental risk factors  
Also the environmental triggers of CLT etiology will be more easily assessed 
once we have identified the genetic risk factors. Then, more thorough and 
unbiased analyses could be done in dogs classified both by clinical 
phenotype (affected, un-affected) as well as genotype (risk, non-risk). 
Attractive theoretical risk factors to investigate in the dog would be canine 
hepatitis C virus infection, vaccination, iodine intake and pregnancy.   51
Practical implications  
Decrease disease prevalence 
After identifying the disease-causing mutations for CLT, development of a 
genetic test would be beneficial for breeders of high-risk breeds, to avoid 
breeding genetically susceptible individuals. However, such a genetic test 
has its limitations. First of all; CLT is a complex trait, although in the giant 
schnauzer it appears to be highly heritable. In other breeds, however, this 
might not be the case. A genetic test for a complex trait will lead to a certain 
proportion of dogs being excluded from breeding for carrying genetic risk 
factors, but never developing the disease themselves, because of avoidance of 
genetic triggers. Also, if not all genetic components are identified, there is a 
risk of including genetically susceptible dogs not detected by the test. 
Second; Genetic risk factors might not be the same in all breeds and all 
populations, therefore a genetic test applied in one breed might not be used 
in another. Third; genetic tests involving the DLA class II region needs 
some consideration. Since DLA class II polymorphism is crucial for 
maintaining a diverse immune response and to sustain viral and bacterial 
infections, one needs to nourish that genetic diversity, even though avoiding 
homozygosity of the risk variant. Fourth, and perhaps the most important in 
the giant schnauzer breed; to employ a genetic test for CLT in a high-risk 
breed such as the giant schnauzer might also be challenging due to the high 
frequency of risk alleles within the population. Since the majority of dogs 
carry the risk alleles, excluding all such dogs from breeding would be 
disastrous, as a very small number of dogs would be left. Instead, while not 
currently acceptable by breed clubs, introducing some novel alleles from a 
different breed might be the biologically most viable option. 
 
Healthier dogs, healthier humans 
Today, no treatment or cure is available for autoimmune hypothyroidism, 
but patients are dependent on life-long L-thyroxine substitution therapy. It 
is a synthetic variant of the lacking thyroxine and even though most patients 
answer well to the treatment, this drug does not stop or cure the disease but 
only treats the symptoms.  
However, unraveling the genetic background of CLT and Hashimoto’s 
disease might lead to drugs designed to slow down, stop or even prevent the 
disease. Perhaps the most extensively studied fields within human medicine 
are those investigating possible disease therapies. Therefore, healthcare 
tailored to suit the genetic makeup of the patient is no longer a science   52
fiction, but will soon be available for several diseases, possibly also for 
patients suffering from CLT and Hashimoto’s disease. Inhibition of NF-kB 
and its related genes have been extensively investigated as therapeutic targets 
for inflammatory and autoimmune diseases (reviewed in(Gilmore & Garbati, 
2011). Hypothetically, a drug designed to specifically suppress TILRR-
activity might soon be investigated as treatment for CLT in dogs and, if it is 
identified as a risk factor also in human AITD, for patients suffering from 
Hashimoto’s disease. 
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Populärvetenskaplig sammanfattning 
Hunden är människans bästa och närmsta vän på många sätt. Vi lever i 
samma miljö, äter i stort ￿sett samma mat och drabbas också i stor 
utsträckning av samma ärftliga sjukdomar. Cancer, diabetes, epilepsi, hjärt-
kärlsjukdomar och autoimmuna sjukdomar förekommer också hos hund, 
och många gånger är sjukdomens uppkomst, utveckling och kliniska 
symtom mycket lika människans. Genom att studera den genetiska orsaken 
till hundens sjukdomar kan vi därför lära oss mycket även om människas 
motsvariga sjukdomar. Den här avhandlingen beskriver studier av 
autoimmun sköldkörtelrubbning, även kallad lymfocytär thyroidit (LT) hos 
hund.  
Lymfocytär thyroidit  
Lymfocytär thyroidit tillhör de organspecifika autoimmuna sjukdomarna och 
drabbar både hundar och människor. Hos människa kallas den Hashimoto’s 
sjukdom, efter den japanska specialist som första gången karaktäriserade 
sjukdomen år 1912. Att sjukdomen är autoimmun och organspecifik innebär 
att kroppen felaktigt uppfattar sitt eget organ som främmande, vilket leder 
till aktivering av immunologiska celler och nedbrytning av kroppsegen 
vävnad. Sköldkörteln är en liten, fjärilsformad körtel som sitter på halsens 
framsida, strax under struphuvudet. Här bildas tyroxin (T4) och trijodtyronin 
(T3), två viktiga hormon som styr kroppens ämnesomsättning. Tillväxt, 
värmereglering, fettförbränning, hjärtfrekvens, fertilitet och många andra 
kroppsfunktioner styrs av T3 och T4. Producerar kroppen för lite 
sköldkörtelhormon ses symtom över nästan hela kroppen. Trötthet, ökad 
vikt, sänkt hjärtfrekvens, frusenhet och håravfall är vanliga symtom både hos 
hund och människa.   54
Förekomsten av lymfocytär thyroidit (LT) hos hund och dess slående 
likheter med Hashimoto’s sjukdom beskrevs för första gången 1968 i en 
flock beaglehundar. Sedan dess har sjukdomen rapporterats som frekvent 
förekommande i många raser och anses idag vara en av de vanligaste 
endokrina sjukdomarna hos hund. I Sverige är de mest frekvent drabbade 
raserna riesenschnauzer och hovawart, men också golden retriever, 
dobermann, cocker spaniel, boxer och rhodesian ridgeback har rapporterats 
vara högriskraser.  
 
Idag finns inga avelsstrategier för att reducera sjukdomen, förutom att 
undvika att använda sjuka hundar och dess nära släktingar i avel. Men 
eftersom LT oftast debuterar i medelålders eller äldre hundar, har denna 
strategi inte varit effektiv. Sjuka hundar har redan hunnit producera sjuka 
avkommor. Med kunskap om de genetiska orsakerna till LT skulle det vara 
möjligt att utveckla ett genetiskt test och på så vis få tillgång till ett mer 
effektivt avelsverktyg. I förlängningen skulle sådan kunskap också kunna 
leda till effektivare diagnoser och skräddarsydda mediciner. 
Syftet med studierna 
Syftet med denna avhandling var att undersöka den genetiska orsaken till 
lymfocytär thyroidit hos hund, vilket även skulle kunna vara till nytta för 
människor med Hashimoto’s sjukdom. Mer specifikt var målet att: 
  
o  Uppskatta frekvensen av LT i riesenschnauzer och hovawart, två raser 
tidigare indikerade som högriskraser. 
 
o  Undersöka DLA klass II som en potentiell genetisk riskfaktor för LT. 
 
o  Identifiera ytterligare genetiska riskfaktorer genom en så kallad 
helgenom-associationsanalys. 
Sammanfattning av studierna 
I vår första studie (artikel I) ville vi undersöka frekvensen av LT i 
riesenschnauzer och hovawart. För att också få en bild över sjukdomens 
utveckling och jämföra frekvensen i olika ålderskategorier samlade vi in 
information och blodprover från två olika årskullar. Hundarna var vid 
provtillfället 3-4 respektive 6-7 år gamla (födda 1995 och 1992). Genom att 
mäta blodets koncentration av sköldkörtelhormon (T4), sköldkörtel-  55
stimulerande hormon (TSH) och förekomst av autoantikroppar mot 
thyroglobulin (TgAA) kunde vi uppskatta förekomsten av LT till 16 % hos 
riesenschnauzer och 13 % hos hovawart. Väldigt få hundar i den yngre 
kategorin hade utvecklat symtom och fått en LT-diagnos vid tiden för 
provtagning, men enligt våra mätningar befann sig mer än 10 % av de unga i 
ett tidigt skede av sjukdomen. Detta är en viktig iakttagelse, eftersom de 
flesta hundar som används som avelsdjur är i denna ålder eller ännu yngre. 
Risken är därför stor att en hund som senare i livet utvecklar LT kan 
komma att användas i avel. Detta kan delvis förklara den höga frekvensen 
sjukdom i dessa två raser. 
I vår nästa studie (artikel II) undersöktes genetiska riskfaktorer för LT 
genom en så kallad kandidatgen-strategi. Tidigare studier har rapporterat ett 
starkt samband mellan Hashimoto’s sjukdom hos människor och variation i 
HLA klass II gener. Dessa gener kodar för protein vars funktion är att 
presentera olika ämnen i kroppen för immunförsvarets celler. Upptäcker 
immuncellerna ett främmande ämne (tex en bakterie eller ett virus) bundet 
till en HLA-molekyl aktiveras ett immunsvar. Eftersom ett samband hade 
setts till Hashimoto’s sjukdom var vår hypotes att hundens motsvarighet till 
HLA, vilken kallas DLA, kan ha inverkan även på LT. Genom att jämföra 
den genetiska sekvensen i tre DLA klass II gener hos 30 sjuka och 74 friska 
riesenschnauzer kunde vi konstatera att en viss kombination av dessa gener 
gav en starkt ökad risk att utveckla LT, medan en annan variant av DLA 
klass II generna istället gav ett ökat skydd mot sjukdomen.  
Vi hade nu identifierat en god studiepopulation och sett att våra 
diagnostiska kriterier var starka nog att hitta genetiska riskfaktorer inom 
riesenschnauzer. Härnäst ville vi undersöka hela arvsmassan i jakt på fler 
gener med inverkan på sjukdomen, eftersom det sedan tidigare är känt att 
både Hashimoto’s sjukdom och LT styrs av flera gener. Genom att 
förutsättningslöst jämföra arvsmassan hos 74 sjuka och 48 friska individer i 
en så kallad helgenoms association kunde vi identifiera två regioner med 
stark koppling till sjukdomen, den ena lokaliserad på kromosom 11 och den 
andra på kromosom X. Båda de associerade områdena innehåller gener som 
tidigare rapporterats ha en stor inverkan på reglering av immunförsvaret. De 
två starkaste signalerna sågs intill generna BCOR (kromosom X) och 
FREM1 (kromosom 11). Intressant är att de båda generna är involverade i 
en och samma signalkaskad, NF-B, som sedan tidigare är känd för sina 
viktiga inflammatoriska och immunologiska effekter. Framtida studier syftar 
till att identifiera den eller de exakta mutationer som ger uppkomst till 
sjukdom, och att förstå den funktionella effekten av dessa mutationer.   56
Slutsatser i korthet 
Resultaten från denna avhandling bidrar med viktig kunskap om 
förekomsten och den genetiska bakgrunden till lymfocytär thyroidit hos 
hund. Vidare visar den tydligt fördelarna med att använda hund i genetisk 
sjukdomsforskning. Mer specifikt kunde följande slutsatser dras:  
  
o  Riesenschnauzer och hovawart är raser med hög förekomst av LT, 
cirka 16 respektive 13 % av hundarna drabbas. I yngre hundar (3-4 år) 
är subklinisk LT vanligt, medan fullt utvecklad sjukdom är vanligare 
hos äldre hundar. 
 
o  En viss variant av DLA klass II generna kan ge ökad risk att utveckla 
LT, medan en annan variant ger ett ökat skydd mot sjukdomen.  
 
o  Ytterligare genetiska riskfaktorer identifierades på kromosom 11 och X. 
Flera av generna i området är involverade i NF-B signalkaskaden, ett 
välkänt reglerelement för immunologiska och inflammatoriska 
sjukdomar hos människa. Detta tyder på att hund är en mycket god 
modell för studier av Hashimoto’s sjukdom.  
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